Exploring the Future of TYK2: Cutting-Edge Research and Therapeutic Implications for Pediatric Dermatology

This new PeDRA webinar explores the latest advancements in TYK2 (Tyrosine Kinase 2) research and examines its potential role in treating various pediatric dermatological conditions. Expert Johann Gudjonsson, MD, PhD, discusses the emerging therapeutic strategies targeting TYK2, their clinical applications, and the future direction of pediatric dermatology treatments. Kelly Cordoro, MD, moderates this excellent program.

Kelly Cordoro, MD

Moderator

No disclosures or conflicts with industry.

---

Read More

Modal Title

close modal

Kelly Cordoro, MD Moderator

---

No disclosures or conflicts with industry.

Close Popup

Johann Gudjosson, MD, PhD

Speaker

Disclosures:

Research Support:

• AbbVie, SunPharma, Eli Lilly, Kyowa Kirin, Almirall, Celgene/BMS, Janssen, Prometheus/Merck, TimberPharma, Boehringer Ingelehim, Novartis

Advocacy Board/Consultant:

• Novartis, MiRagen, AbbVie, Eli Lilly, Almirall, Galderma, Boehringer Ingelehim, Celgene/BMS, Sanofi, Janssen, AnaptysBio

---

Read More

Modal Title

close modal

Johann Gudjosson, MD, PhD Speaker

---

Disclosures:

Research Support:

• AbbVie, SunPharma, Eli Lilly, Kyowa Kirin, Almirall, Celgene/BMS, Janssen, Prometheus/Merck, TimberPharma, Boehringer Ingelehim, Novartis

Advocacy Board/Consultant:

• Novartis, MiRagen, AbbVie, Eli Lilly, Almirall, Galderma, Boehringer Ingelehim, Celgene/BMS, Sanofi, Janssen, AnaptysBio

Close Popup

This webinar is hosted by PeDRA with support from an independent medical education grant from Bristol Myers Squib.  PeDRA is solely responsible for all program content and the selection of all presenters, authors, moderators, and faculty.